Allergy Therapeutics (LON:AGY) Hits New 52-Week Low – Here’s Why

Allergy Therapeutics plc (LON:AGY) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 5 and last traded at GBX 5.17, with a volume of 525312 shares changing hands. The stock had previously closed at GBX 5.50.

Allergy Therapeutics Trading Down 5.9%

The company has a market capitalization of £327.71 million, a P/E ratio of -5.34, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a 50-day simple moving average of GBX 6.84 and a 200 day simple moving average of GBX 9.28. The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.